Gabapentin Capsule
Product Images NDC 71610-667

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71610-667). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 100 mg (71610 0667 30)

Gabapentin 100 mg capsules label displaying the product name, strength, dosage form, and NDC number 71610-0667-30. The label instructs storage at 20-25°C and advises dispensing in a tight light-resistant container. Manufactured by SageGen Pharmaceuticals Inc., Hauppauge, NY, and repackaged by Aphena Pharma, Cookeville, TN. The package contains 30 capsules for oral use.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Figure 1 (Image 01)

A line graph comparing mean pain scores over 8 weeks between a placebo group and a Gabapentin group (3600 mg/day). The x-axis shows weeks, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows the mean pain score from 0 to 10. The graph indicates a decrease in pain score for the Gabapentin group, while the placebo group remains relatively stable.*

FDA Label Image

Figure 2 (Image 02)

A line graph depicting mean pain scores over seven weeks, comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks, including a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10, illustrating a decrease in pain scores with Gabapentin doses compared to placebo over time.*

FDA Label Image

Figure 3 (Image 03)

A bar graph titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It presents data from two studies comparing placebo (PBO) and different dosages of Gabapentin (GBP 1800, 2400, and 3600 mg). The y-axis shows response proportion from 0% to 100%. Study 1 shows 12% response for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg, with statistical significance indicators (p < 0.01 and p < 0.001).*

FDA Label Image

Cockcroft And Gault Equation (Image 04)

A formula panel displaying the equation to calculate creatinine clearance (CLCr), involving age, weight, serum creatinine, and a factor for female patients. This is a typical calculation reference found in drug labeling or pharmacokinetic information.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of Gabapentin showing the cyclohexane ring with attached amino and carboxyl groups. This molecular diagram represents the active ingredient Gabapentin in the product.*

FDA Label Image

Image-09 (Image 09)

A scatter plot chart showing the difference percentage versus daily dose of gabapentin (mg). The chart compares three studies labeled as Study a, Study b, and Study c, with daily doses from about 600 mg to 1800 mg on the x-axis and difference percentage from around 7% to 18% on the y-axis.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.